Proteins for life
ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.
The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.

Latest press release
Pareto and Analysguiden publish research reports
Hørsholm, Denmark, 16 March 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in March. Both sponsored research analysts commented on the recently announced rights issue and MucoVax collaboration. Analysguiden reduced its price target to SEK 12 per share, primarily…
Read more